- US-listed companies
- OCULAR THERAPEUTIX, INC
- Income statement
OCULAR THERAPEUTIX, INCOCUL
Market cap
$2.4B
P/E ratio
| 2014/12 | 2015/12 | 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | |
| Revenue | 1 | 2 | 2 | 2 | 2 | 4 | 17 | 44 | 51 | 58 | 64 |
| Revenue growth (%) | - | ||||||||||
| Cost of revenue | 0 | 0 | 0 | 0 | - | 2 | 2 | 4 | 5 | 5 | 6 |
| Research & development | 19 | 27 | 27 | 31 | 37 | 41 | 29 | 50 | 53 | 61 | 128 |
| Operating margin (%) | |||||||||||
| Operating income | -27 | -38 | -43 | -62 | -59 | -86 | -63 | -78 | -79 | -82 | -172 |
| Operating expenses | 28 | 40 | 45 | 64 | 61 | 90 | 80 | 122 | 130 | 141 | 236 |
| Net income | -29 | -40 | -45 | -63 | -60 | 86 | -156 | -7 | -71 | -81 | -194 |
| Net income margin (%) | |||||||||||
| Earnings per share | - | - | - | - | - | - | - | -0.09 | -0.92 | -1.01 | -1.22 |
| Diluted EPS | - | - | - | - | - | - | - | -0.98 | -0.97 | -1.02 | -1.22 |
| EBITDA | |||||||||||
| EBITDA margin (%) |